peripheral neuropathy

Cataracts, Congenital, and Hypomyelinating Leukodystrophy

Clinical Characteristics
Ocular Features: 

Bilateral cataracts may be present at birth or later in the first decade of life.  The ERG and flash VEPs are normal.

Systemic Features: 

Psychomotor development is initially normal but signs of delay are usually present during the first year of life.  Patients may be able to walk but only with support.  Pyramidal and cerebellar dysfunction, muscle weakness and wasting, dysarthria, truncal hypotonia, intention tremor, and spasticity are evident during the first decade.  Some have seizures.  Cognitive impairment ranges from mild to moderate.  Most patients become wheelchair-bound late in the first decade of life and some do not survive beyond childhood.

Hypomyelination and mild axonal loss may be seen in peripheral nerve biopsies while neuroimaging shows evidence of diffuse and progressive cerebral white matter atrophy.

Genetics

This is an autosomal recessive disorder caused by homozygous mutations in FAM126A (7p15.3) leading to a deficiency of the neuronal protein hyccin.  The result is deficient myelination in both central and peripheral nervous systems.  No symptoms are evident in heterozygotes.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

The cataracts may be surgically removed.  There is no known treatment for the progressive neurologic deterioration but physical therapy and special education may be helpful.

References
Article Title: 

Novel FAM126A mutations in Hypomyelination and Congenital Cataract disease

Traverso M, Assereto S, Gazzerro E, Savasta S, Abdalla EM, Rossi A, Baldassari S, Fruscione F, Ruffinazzi G, Fassad MR, El Beheiry A, Minetti C, Zara F, Biancheri R. Novel FAM126A mutations in Hypomyelination and Congenital Cataract disease. Biochem Biophys Res Commun. 2013 Aug 30. [Epub ahead of print] PubMed PMID: 23998934.

PubMed ID: 
23998934

Phenotypic characterization of hypomyelination and congenital cataract

Biancheri R, Zara F, Bruno C, Rossi A, Bordo L, Gazzerro E, Sotgia F, Pedemonte M, Scapolan S, Bado M, Uziel G, Bugiani M, Lamba LD, Costa V, Schenone A, Rozemuller AJ, Tortori-Donati P, Lisanti MP, van der Knaap MS, Minetti C. Phenotypic characterization of hypomyelination and congenital cataract. Ann Neurol. 2007 Aug;62(2):121-7.

PubMed ID: 
17683097

Wilson Disease

Clinical Characteristics
Ocular Features: 

The cornea and lens have visible copper deposition.  This is responsible for the classic (though non-pathognomonic) copper-colored Kayser-Fleischer ring in the cornea where evidence of copper deposition can be visualized in the posterior stroma and in the endothelium.  About 50-60% of patients at any point have evidence of such copper deposition but the number rises to 90% in patients with neurologic and psychiatric symptoms.  Copper deposition in the lens leads to a ‘sunflower’ or 'sunburst' cataract consisting of a greenish central disc in the anterior capsule with spoke-like radial cortical opacities.  Eye involvement in Wilson disease usually does not lead to significant impairment of vision.

Systemic Features: 

This is a disorder of copper metabolism.  It is associated with severe liver disease, often beginning with signs of recurrent jaundice, sometimes a hepatitis-like illness, and often culminating in liver failure.  Hepatobiliary malignancies are a significant risk, occurring in more than 1 percent of patients.  Neurologic toxicity leads to various movement disorders such as tremors, poor coordination, dystonia, and choreoathetosis.  Many patients have mental symptoms such as depression, neurotic behavior, and personality disturbances.  Some have a mask-like facies and pseudobulbar symptoms.  Symptoms can appear anytime from 3 years of age to over 50.  Other organs such as kidney, pancreas, heart and even joints may also be involved.

Patients often have a low serum ceruloplasmin, low copper levels, increased urinary excretion of copper, and increased concentration of copper in the liver.

Genetics

This is an autosomal recessive disorder caused by homozygous or doubly heterozygous mutations in the ATP7B gene (13q14.3).  Heterozygotes usually do not develop symptoms but may have reduced serum ceruloplasmin levels.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

Zinc and/or copper chelating agents such as D-penicillamine or trientine have long been used with benefit but the treatment must be used throughout life.  Reduced copper intake may also be helpful.  An orthotopic liver transplant can prolong life in selected patients.

References
Article Title: 

Hepatobiliary malignancies in Wilson disease.

Pfeiffenberger J, Mogler C, Gotthardt DN, Schulze-Bergkamen H, Litwin T, Reuner U, Hefter H, Huster D, Schemmer P, Czlonkowska A, Schirmacher P, Stremmel W, Cassiman D, Weiss KH. Hepatobiliary malignancies in Wilson disease. Liver Int. 2014 Nov 4. [Epub ahead of print].

PubMed ID: 
25369181

A practice guideline on Wilson disease

Roberts EA, Schilsky ML; Division of Gastroenterology and Nutrition, Hospital for Sick Children, Toronto, Ontario, Canada. A practice guideline on Wilson disease. Hepatology. 2003 Jun;37(6):1475-92. Erratum in: Hepatology. 2003 Aug;38(2):536.

PubMed ID: 
12774027

Krabbe Disease

Clinical Characteristics
Ocular Features: 

Subtle cherry red spots have been reported in one patient.  More than half (53%) have abnormal VEP response but the ERG is normal.  Optic atrophy with blindness is not uncommon but the full ocular phenotype remains unknown.  A 6-month-old male child had MRI T2 evidence of intracranial optic nerve hypertrophy which was attributed to an accumulation of globoid cells.

Systemic Features: 

There is considerable variation in the time of onset and rate of progression in Krabbe disease, even within families.  Patients with infantile disease may present with symptoms at about 6 months of life, while others are not diagnosed until late childhood or adolescence.  Some evidence of psychomotor retardation is often the first sign of disease with ataxia and limb spasticity soon following.  Irritability is an early sign.  Neurophysiologic studies often show abnormal nerve conduction and this has been documented even in newborns.  The disorder is one of progressive neurodegeneration of both central and peripheral nervous systems leading to weakness, seizures and loss of protective reflexes.  The MRI may reveal T2 hyperintensity in cerebral and cerebellar white matter, internal capsules and pyramidal tracts.  Infection and respiratory failure are responsible for most deaths.

The life-span of Infants with Krabbe disease is approximately one year while those with late-onset disease may not develop symptoms until almost any age and the clinical course is highly variable.

Genetics

This is an autosomal recessive disorder secondary to mutations in the GALC gene (14q31) encoding the enzyme galactosylceramidase, important in the growth and maintenance of myelin.

One patient has been reported with ‘atypical’ Krabbe disease (611722) secondary to a homozygous mutation in the PSAP gene (10q22.1).  The infant had a deficiency of saposin A as well as decreased galactocerebrosidase activity in white blood cells

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

Normal blood galactocerebrosidase can be restored and CNS deterioration may be delayed or improved with transplantation of allogeneic hematopoietic stem cells or umbilical cord blood.   However, some patients have residual language deficits and mild to severe delays in motor function.  Results are better if treatment is commenced during infancy before development of symptoms.  These treatments are experimental and long range outcomes remain uncertain.

References
Article Title: 

Chédiak-Higashi Syndrome

Clinical Characteristics
Ocular Features: 

The ocular hypopigmentation and visual function deficits in Chediak-Higashi syndrome resembles that of other types of albinism.  The iris has transillumination defects and the retina is hypopigmented.  Patients are photophobic and often have nystagmus.  Due to the early mortality of many patients, vision is difficult to measure, but is said to range from normal to near normal.  Hair bulb incubations studies show normal pigmentation.

A  subset of patients with later onset of disease has been reported to have optic atrophy, thinning of the nerve fiber layer, and a central scotoma.

Systemic Features: 

This is a form of albinism with other systemic features such as adenopathy, hepatosplenomegaly, neutropenia, and susceptibility to infection (especially gram positive organisms).  The hypopigmentation is evident at birth but may be patchy.  The hair has been described as having a blue-green metallic sheen.  It may also be sparse.  Patients have an increased risk of leukemia and lymphoma-like disease.  Peripheral sensory-motor neuropathy and ataxia are common in older individuals.  Thrombocytopenia can lead to easy bruising and extensive bleeding.  Neutrophils are often few in number and deficient in chemotactic and bacterial activity.  Pyoderma and peridontitis can be severe.  Survival without treatment is between 3 and 4 years but those who survive eventually develop lymphohistiocytic infiltration of major organs, bone marrow and peripheral nerves as young adults.

Giant peroxidase-positive inclusions in white blood cells are diagnostic.

Genetics

This is an autosomal recessive disorder caused by mutations in the LYST gene (1q42.1-q42.2) causing defects in vesicle trafficking.

Hermansky-Pudlak syndrome (214500) is another form of hypopigmentation with serious systemic manifestations.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

Bone marrow transplantation can prolong life but neurologic symptoms often develop in those who survive.  Low-vision aids can be helpful.  Infections, of course, should be promptly and vigorously treated.

References
Article Title: 

Optic neuropathy in late-onset neurodegenerative Chédiak-Higashi syndrome

Desai N, Weisfeld-Adams JD, Brodie SE, Cho C, Curcio CA, Lublin F, Rucker JC. Optic neuropathy in late-onset neurodegenerative Chediak-Higashi syndrome. Br J Ophthalmol. 2015 Aug 25. pii: bjophthalmol-2015-307012. doi: 10.1136/bjophthalmol-2015-307012. [Epub ahead of print].

PubMed ID: 
26307451

Chédiak-Higashi syndrome

Kaplan J, De Domenico I, Ward DM. Chediak-Higashi syndrome. Curr Opin Hematol. 2008 Jan;15(1):22-9. Review. PubMed PMID: 18043242.

PubMed ID: 
18043242

Charcot-Marie-Tooth Disease with Glaucoma

Clinical Characteristics
Ocular Features: 

Optic atrophy can be an ocular manifestation of CMT disease, especially in the X-linked forms, but this variant is the only one in which early-onset glaucoma is a feature.  It may begin at birth in some patients who have features of congenital glaucoma such as buphthalmos, while in other family members, including juveniles, only elevated intraocular pressures were reported.  Optic nerve damage seems to occur rapidly.

Systemic Features: 

This is a sensorineural disease of myelination that causes a polyneuropathy with muscular weakness and sensory deficits.  CMT4B2 is characterized by abnormal myelin sheath folding.  Symptoms of lower limb weakness and evidence of muscle atrophy commonly appear in the middle of the first decade with progression to upper limb involvement.  Areflexia follows with development of pes cavus and hammertoes.  Motor nerve conduction velocities may be severely reduced and muscle biopsies show severe loss of myelinated fibers and focal myelin sheath folding.

Genetics

This seems to be an autosomal recessive disorder although only a few families have been reported.  Homozygous mutations in the SBF2 gene (sometimes called MTMR13) (11p15.4) were found in these CMT families with early-onset glaucoma (604563).  This gene codes for SET binding factor 2 important to the normal development of the trabecular meshwork.  Not all SBF2 mutations cause glaucoma though.  Of course, it is possible that the occurrence of glaucoma is incidental and not part of CMT4B2 at all.

A clinically similar neurological condition without glaucoma, CMT4B1 (601382), has been reported to be caused by a mutation in MTMR2 located at 11q22 (601382). 

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

Little is known about the natural history of the glaucoma in this condition but it occurs early and severe visual loss seems to be common.  Early diagnosis and vigorous treatment are important.  The neurological disease requires a multidisciplinary approach with physical therapists, neurologists, orthopedic surgeons and the use of prostheses.

References
Article Title: 

Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma

Azzedine H, Bolino A, Taieb T, Birouk N, Di Duca M, Bouhouche A, Benamou S, Mrabet A, Hammadouche T, Chkili T, Gouider R, Ravazzolo R, Brice A, Laporte J, LeGuern E. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet. 2003 May;72(5):1141-53.

PubMed ID: 
12687498

Cerebrotendinous Xanthomatosis

Clinical Characteristics
Ocular Features: 

Juvenile cataracts are the primary ocular feature of this disorder and are found in virtually all patients.  These often cause the first symptoms and become evident in the first decade and almost always by the third decade of life.  Lens opacification may require extraction at that time and aspirated lens material may contain lipid-containing vacuoles.  However, some cataracts may not be diagnosed until the 5th or 6th decades after the onset of neurological symptoms, usually because the opacities are located in the peripheral cortex and do not cause visual symptoms. 

Optic atrophy occurs in nearly half of affected individuals.  Yellowish flakes resembling cholesterol crystals can sometimes be seen in the vitreous. The fundus may have scattered hard exudates and cholesterol-like deposits along the vascular arcades and arterioles show evidence of atherosclerosis.  RPE window defects are common.

Systemic Features: 

CTX has serious systemic neurologic signs and symptoms resulting from a deficiency of a mitochondrial enzyme, sterol 27-hydroxylase.  The result is reduced bile acid synthesis and increased levels of cholestanol in plasma, tissues, and CSF.  This results in a characteristic phenotype of tendon xanthomas, and neurological dysfunction including mental regression or illness, cerebellar ataxia, peripheral neuropathy, seizures, and pyramidal signs to various degrees.  Neonatal jaundice and diarrhea are common.

Genetics

This autosomal recessive disorder results from a mutation in the CYP27A1 gene (2q33-qter) encoding sterol 27-hydroxylase.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

This is a treatable disorder in which administration of chenodeoxycholic acid (CDCA) is beneficial.  This compound is virtually absent from bile in people with CTX.  Exogenous administration reduces high levels of cholesterol and cholestanol in the CSF, tissues, and plasma with improvement in mental function and signs of peripheral neuropathy and cerebellar dysfunction.  It is frequently given in combination with other HMG-CoA inhibitors such as pravastatin.  Early diagnosis and treatment are important.

References
Article Title: 

Fabry Disease

Clinical Characteristics
Ocular Features: 

Fabry disease is a lysosomal enzyme (alpha-galactosidase A) deficiency resulting in the accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids throughout the body.  The signature ocular manifestation is the whorl-like corneal pattern of lipid (glycosphingolipid) deposits which are present in both hemizygous males and heterozygous females.  These are sometimes referred to as cornea verticillata or Fleischer vortex dystrophy with a pattern similar to that seen in some patients using atabrine or amiodarone.  A general 'haze' throughout the cornea is even more common.  Lens opacities may also be distinctive and generally are one of two types: spoke-like opacities beneath the posterior capsule among males, and wedge-shaped anterior subcapsular deposits, again primarily in males.  The corneal and lens opacities seldom cause significant vision problems.

Involvement of the ocular vessels is present in almost all patients.  A notable increase in tortuosity of conjunctival vessels is present in 97% of hemizygous males and 78% of heterozygous females.  Increased retinal vessel tortuosity is less common but arteriolar involvement significantly increases the risk of central retinal artery occlusions.  An 11 yo Turkish female heterozygote with a cilioretinal artery occlusion and anterior ischemic optic neuropathy in one eye has been reported.

Systemic Features: 

The relatively common occurrence and the protean nature of Fabry disease has lead to its designation by some as the Great Imposter, replacing syphilis to which this term was previously applied.  Compounding the diagnostic difficulties in some individuals is the absence of the complete classical phenotype due to the presence of DNA variants that may modify the expression of some the clinical features.

Most signs present in the first or second decade of life with generally earlier onset in males.  The presence of proteinuria before the age of 20 years in the absence of other primary kidney disease should always raise the possibility of Fabry disease.  However, the diagnosis is often not made until the third decade in males and the fourth decade in females.  Glycosphingolipid inclusion deposits in endothelial cells are responsible for the systemic signs and symptoms including renal and heart disease which are the most common causes of premature death.  Small vessel involvement resulting in cerebrovascular disease and painful peripheral neuropathy can be debilitating. The risk of ischemic strokes is increased.  Cardiac manifestations include hypertrophic cardiomyopathy (60%), mainly involving the left ventricle, and dysfunction of the mitral and aortic valves (10 to 25%).  Dysfunction of renal glomeruli may progress to renal failure by the third to fifth decade in males.  The angiokeratomas and angiomas (most pronounced in a swimming trunk pattern) are secondary to vascular involvement of cutaneous vessels but are non-specific since they also occur in other lysosomal diseases.  The life expectancy of females is reduced by about 5 years and for males about 16 years compared with the general US population.

Involvment of the autonomic system manifests as intermittent fever, hypohidrosis, and poor temperature control.  Some patients have periodic crises of severe pain in the extremities as well as intermittent epigastric pain. Hearing loss and episodic tinnitus are common complaints.

Genetics

This is an X-linked disorder and generally assumed to be recessive although some have suggested dominance since most heterozygous females have significant manifestations that can be life-threatening.  The mutations in the responsible gene (GLA), located at Xq22, involve a variety of deletions, rearrangements and single base pair changes.  Defects in the GLA gene lead to dysfunction of the enzyme alpha-galactosidase A resulting in lysosomal deposition of glycosphingolipids throughout the body, especially in vascular endothelial cells.   

The milder disease and increase in the range of clinical manifestations among females is likely a reflection of variable patterns of X-inactivation.

Increased tortuosity of retinal arterioles is also seen in fucidosis (230000), Williams syndrome (194050), and in a condition known as retinal arteriolar tortuosity (611773, 180000).

Pedigree: 
X-linked dominant, father affected
X-linked dominant, mother affected
Treatment
Treatment Options: 

Enzyme replacement therapy using agalsidase alfa (commercially available as Febrazyme (tm)) have shown promise as measured by renal function, pain intensity, left ventricular size, and general quality of life.  However, the impact on longevity remains to be determined.  Evidence suggests that early treatment is associated with improved outcomes. The corneal and lenticular opacities generally do not require treatment.

Continuous release of cardiac troponin I (cTNI) with elevated serum levels may be a clue to the severity of heart involvement.

References
Article Title: 

Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease

Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, Biegstraaten M, Mehta A, Hollak CEM, Langeveld M. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab. 2017 May 4. pii: S1096-7192(17)30156-7.

PubMed ID: 
28495078

Continuous cardiac troponin I release in fabry disease

Feustel A, Hahn A, Schneider C, Sieweke N, Franzen W, Gunduz D, Rolfs A, Tanislav C. Continuous cardiac troponin I release in fabry disease. PLoS One. 2014 Mar 13;9(3):e91757. doi: 10.1371/journal.pone.0091757. eCollection 2014.

PubMed ID: 
24626231

Fabry disease: overall effects of agalsidase alfa treatment

Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A,
Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest. 2004 Dec;34(12):838-44.

PubMed ID: 
15606727

Tangier Disease

Clinical Characteristics
Ocular Features: 

This disorder of lipoprotein metabolism is associated in many cases with corneal infiltrates, cicatricial ectropion, poor lid closure, and exposure keratopathy.  The corneal clouding alone generally cause little reduction of acuity but those with poor lid function and exposure keratopathy may have severe vision loss.  There may be weakness in the periorbital and lid muscles.  The corneal infiltration occurs late in life but is progressive with older individuals having the greatest visual impairment.  The corneal infiltrates are described as a “dot-like haze”, more prominent centrally and located in the stroma.  On electron microscopy, deposits in the conjunctiva are described as birefringent lipid particles located in pericytes and fibrocytes.  Lipid deposition occurs throughout the body including the conjunctiva.  Corneal hypesthesia has been reported.

In a series of 13 patients, ectropion and corneal scarring were reported in 3 and corneal infiltrates in 9.  Four had orbicular muscle weakness.  The latter together with corneal hypesthesia may be the earliest ocular signs of Tangier disease and should suggest the diagnosis even before the corneal clouding occurs.

Systemic Features: 

Patients with Tangier disease have significant enlargement of the liver, spleen and lymph nodes.  The tonsils are also frequently enlarged and have a characteristic yellow-orange  coloration.  The enlargement of these organs is due to lipid infiltration.  Plasma levels of cholesterol and HDL are characteristically slightly low while triglycerides are mildly elevated.  Peripheral neuropathy and muscle atrophy can be debilitating.  Severe coronary artery disease is common with onset sometime in the 5th decade.

Genetics

Tangier disease is an autosomal recessive disorder resulting from mutations in the ATP-binding cassette-1 gene ABCA1 (9p31.1) located in exon 22.  Parental consanguinity is common.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

No treatment is available for this disorder beyond local organ treatment as indicated.
 

References
Article Title: 

Ocular complications of Tangier disease

Pressly, T. A.; Scott, W. J.; Ide, C. H.; Winkler, A.; Reams, G. P. : Ocular complications of Tangier disease. Am. J. Med. 83: 991-994, 1987.

PubMed ID: 
3314502

Pages

Subscribe to RSS - peripheral neuropathy